$MD
Pediatrix Medical Group, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024091193 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $511.2M $504.3M
YoY Change 0.9% 0.74%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $423.0M $414.4M
YoY Change -0.66% 0.56%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $6.254M $8.791M
YoY Change -32.1% -1.72%
% of Gross Profit
Operating Expenses $477.3M $662.0M
YoY Change 2.36% 46.44%
Operating Profit $33.83M -$157.7M
YoY Change -16.0% -425.22%
Interest Expense -$8.592M $10.31M
YoY Change -182.82% -207.93%
% of Operating Profit -25.4%
Other Income/Expense, Net -$8.592M -$10.01M
YoY Change -8.98% 4.75%
Pretax Income $25.24M -$167.7M
YoY Change -18.15% -530.66%
Income Tax $5.794M -$14.70M
% Of Pretax Income 22.96%
Net Earnings $19.44M -$153.0M
YoY Change -9.12% -641.07%
Net Earnings / Revenue 3.8% -30.34%
Basic Earnings Per Share $0.23 -$1.84
Diluted Earnings Per Share $0.23 -$1.84
COMMON SHARES
Basic Shares Outstanding 85.87M 84.15M
Diluted Shares Outstanding 84.52M 83.33M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $220.5M $133.2M
YoY Change 76.76% 27.66%
Cash & Equivalents $103.8M $19.40M
Short-Term Investments $116.6M $113.8M
Other Short-Term Assets $9.480M $9.941M
YoY Change 20.52% -55.97%
Inventory
Prepaid Expenses $10.19M $11.91M
Receivables $286.9M $274.2M
Other Receivables $1.198M $0.00
Total Short-Term Assets $528.2M $429.2M
YoY Change 25.61% 7.91%
LONG-TERM ASSETS
Property, Plant & Equipment $41.92M $47.89M
YoY Change -44.21% -65.89%
Goodwill $1.239B $1.239B
YoY Change -19.13% -19.13%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $78.59M $79.54M
YoY Change -27.23% -63.59%
Total Long-Term Assets $1.549B $1.566B
YoY Change -18.74% -17.91%
TOTAL ASSETS
Total Short-Term Assets $528.2M $429.2M
Total Long-Term Assets $1.549B $1.566B
Total Assets $2.077B $1.995B
YoY Change -10.72% -13.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.37M $32.00M
YoY Change 49.44% 3.25%
Accrued Expenses $303.1M $254.1M
YoY Change 3.56% -5.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $19.28M $17.73M
YoY Change 29.12% 18.84%
Total Short-Term Liabilities $373.1M $310.2M
YoY Change 6.46% -3.17%
LONG-TERM LIABILITIES
Long-Term Debt $607.4M $612.6M
YoY Change -2.29% -8.05%
Other Long-Term Liabilities $33.04M $31.52M
YoY Change 5.92% -90.7%
Total Long-Term Liabilities $33.04M $31.52M
YoY Change 5.92% -96.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $373.1M $310.2M
Total Long-Term Liabilities $33.04M $31.52M
Total Liabilities $1.344B $1.289B
YoY Change -1.03% -5.45%
SHAREHOLDERS EQUITY
Retained Earnings -$279.0M -$298.5M
YoY Change 1007.93% 540.82%
Common Stock $1.012B $1.007B
YoY Change 1.51% 1.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $732.5M $706.5M
YoY Change
Total Liabilities & Shareholders Equity $2.077B $1.995B
YoY Change -10.72% -13.45%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $19.44M -$153.0M
YoY Change -9.12% -641.07%
Depreciation, Depletion And Amortization $6.254M $8.791M
YoY Change -32.1% -1.72%
Cash From Operating Activities $91.84M $107.0M
YoY Change 14.89% 20.1%
INVESTING ACTIVITIES
Capital Expenditures $6.290M $6.962M
YoY Change -31.29% -14.38%
Acquisitions
YoY Change
Other Investing Activities $1.952M -$5.930M
YoY Change -140.25% 161.58%
Cash From Investing Activities -$4.338M -$12.89M
YoY Change -69.02% 23.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.071M -82.65M
YoY Change -93.93% 4.72%
NET CHANGE
Cash From Operating Activities 91.84M 107.0M
Cash From Investing Activities -4.338M -12.89M
Cash From Financing Activities -3.071M -82.65M
Net Change In Cash 84.43M 11.40M
YoY Change 450.74% -4246.91%
FREE CASH FLOW
Cash From Operating Activities $91.84M $107.0M
Capital Expenditures $6.290M $6.962M
Free Cash Flow $85.55M $99.99M
YoY Change 20.86% 23.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-10873000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
662019000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
452079000
us-gaap Operating Expenses
OperatingExpenses
1141228000
us-gaap Operating Expenses
OperatingExpenses
913046000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-157723000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
48498000
us-gaap Operating Income Loss
OperatingIncomeLoss
-141831000
us-gaap Operating Income Loss
OperatingIncomeLoss
78539000
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
-161000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1189000
us-gaap Investment Income Net
InvestmentIncomeNet
1852000
us-gaap Investment Income Net
InvestmentIncomeNet
1823000
CY2024Q2 us-gaap Interest Expense
InterestExpense
10308000
CY2023Q2 us-gaap Interest Expense
InterestExpense
11230000
us-gaap Interest Expense
InterestExpense
20907000
us-gaap Interest Expense
InterestExpense
21620000
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
464000
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
490000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
982000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
917000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10005000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9551000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18073000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18880000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-167728000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
38947000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-159904000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
59659000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-14703000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10665000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10914000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17171000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-153025000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
28282000
us-gaap Profit Loss
ProfitLoss
-148990000
us-gaap Profit Loss
ProfitLoss
42488000
CY2024Q2 md Net Of Tax Unrealized Holding Gain Loss On Investments
NetOfTaxUnrealizedHoldingGainLossOnInvestments
66000
CY2023Q2 md Net Of Tax Unrealized Holding Gain Loss On Investments
NetOfTaxUnrealizedHoldingGainLossOnInvestments
126000
md Net Of Tax Unrealized Holding Gain Loss On Investments
NetOfTaxUnrealizedHoldingGainLossOnInvestments
86000
md Net Of Tax Unrealized Holding Gain Loss On Investments
NetOfTaxUnrealizedHoldingGainLossOnInvestments
353000
CY2024Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
200000
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-387000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
260000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
217000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-152825000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
27895000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-148730000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
42705000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000893949
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12111
dei Entity Registrant Name
EntityRegistrantName
Pediatrix Medical Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3667538
dei Entity Address Address Line1
EntityAddressAddressLine1
1301 Concord Terrace
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunrise
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33323
dei City Area Code
CityAreaCode
954
dei Local Phone Number
LocalPhoneNumber
384-0175
dei Security12b Title
Security12bTitle
Common Stock, par value $.01 per share
dei Trading Symbol
TradingSymbol
MD
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
85865841
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19402000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73258000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
113795000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
104485000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
274164000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
272313000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11910000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
13525000
CY2024Q2 us-gaap Income Tax Receivable
IncomeTaxReceivable
0
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
7565000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
9941000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
12308000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
429212000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
483454000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47893000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75639000
CY2024Q2 us-gaap Goodwill
Goodwill
1239007000
CY2023Q4 us-gaap Goodwill
Goodwill
1384166000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10193000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21240000
CY2024Q2 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
65392000
CY2023Q4 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
70294000
CY2024Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
124115000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
102852000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
79539000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82165000
CY2024Q2 us-gaap Assets
Assets
1995351000
CY2023Q4 us-gaap Assets
Assets
2219810000
CY2024Q2 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
267333000
CY2023Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
350798000
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
17730000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
14913000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18764000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21076000
CY2024Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
6329000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2159000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
310156000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
388946000
CY2024Q2 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
612640000
CY2023Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
618421000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49176000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47238000
CY2024Q2 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
254770000
CY2023Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
251284000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
30627000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
34308000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31521000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
30552000
CY2024Q2 us-gaap Liabilities
Liabilities
1288890000
CY2023Q4 us-gaap Liabilities
Liabilities
1370749000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85753258
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85753258
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84018023
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84018023
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
858000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
840000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1006018000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
999906000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1954000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2214000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-298461000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149471000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
706461000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
849061000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1995351000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2219810000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
504296000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
500577000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
999397000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
991585000
CY2024Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
357808000
CY2023Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
354032000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
726946000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
716267000
CY2024Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
32369000
CY2023Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
31089000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
63454000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
61809000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56565000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
58013000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
116763000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
117072000
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8791000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8945000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19099000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17898000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
13579000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
22059000
us-gaap Restructuring Charges
RestructuringCharges
0
CY2024Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
154243000
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
154243000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
20112000
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
20112000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
7679000
CY2023Q2 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
7679000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2024Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-10873000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83332000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82399000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83074000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82033000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83332000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82664000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83074000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82377000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
849061000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
4035000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
60000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
860000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3067000
CY2024Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
887000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
856196000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-153025000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
200000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1149000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1952000
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
706461000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
891632000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
14206000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
604000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1095000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3009000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
775000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
909771000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
28282000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-387000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1594000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3126000
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
942375000
us-gaap Net Income Loss
NetIncomeLoss
-148990000
us-gaap Net Income Loss
NetIncomeLoss
42488000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19099000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17898000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
440000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
733000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
154243000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
20112000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
7679000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-10873000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0
us-gaap Share Based Compensation
ShareBasedCompensation
5019000
us-gaap Share Based Compensation
ShareBasedCompensation
6135000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-25028000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
8376000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1678000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
900000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
934000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-28900000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3703000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2141000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-16955000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-5052000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-82917000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-97315000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
11735000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-12028000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
8039000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
838000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-11630000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-10356000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13280000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8038000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-4995000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-3825000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18275000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11863000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
8167000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1667000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
39915000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
17761000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
31244000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
12810000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
12292000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
15130000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29130000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21748000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
235500000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
421000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
235500000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
384000000
md Payments To Term Loan
PaymentsToTermLoan
6250000
md Payments To Term Loan
PaymentsToTermLoan
6250000
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
1391000
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
1404000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2009000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2689000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
898000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
786000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
79000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1613000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6451000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29636000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-53856000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3975000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73258000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9824000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19402000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5849000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
113795000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
104485000
CY2024Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1490865000
CY2023Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1379213000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1216701000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1106900000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
274164000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
272313000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
504296000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
500577000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
999397000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
991585000
CY2024Q2 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2023Q2 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2024Q2 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
9100000
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
400000
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
200000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
20100000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
7700000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
8100000
CY2024Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-10900000
md Good Will Impairment Loss Excluding Deferred Tax Assets Charge
GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge
130000000
CY2024Q2 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
24200000
md Incremental Non Cash Charge
IncrementalNonCashCharge
24200000
md Non Cash Charge
NonCashCharge
154200000
md Change In Rate Of Control Premium
ChangeInRateOfControlPremium
0.01
md Change In Non Cash Impairment Charges
ChangeInNonCashImpairmentCharges
6500000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
32000000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
34588000
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
115093000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
193112000
CY2024Q2 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
28034000
CY2023Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
36545000
CY2024Q2 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
28966000
CY2023Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
32039000
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
8258000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
8262000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
54982000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46252000
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
267333000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
350798000
md Increase Decrease In Accrued Salaries And Bonuses
IncreaseDecreaseInAccruedSalariesAndBonuses
78000000
CY2024Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.05375
us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022
us-gaap Debt Instrument Description
DebtInstrumentDescription
Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions
CY2024Q2 md Purchase Price
PurchasePrice
1.01
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83332000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82399000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83074000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82033000
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
265000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
344000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83332000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82664000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83074000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82377000
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
916000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1338000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
661000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1358000
CY2024Q2 md Incremental Shares Not Included Due To Anti Dilutive Effect
IncrementalSharesNotIncludedDueToAntiDilutiveEffect
100000
md Incremental Shares Not Included Due To Anti Dilutive Effect
IncrementalSharesNotIncludedDueToAntiDilutiveEffect
300000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2000000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4900000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6100000
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2018Q3 srt Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
500000000
CY2023Q4 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
4600000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-091193-index-headers.html Edgar Link pending
0000950170-24-091193-index.html Edgar Link pending
0000950170-24-091193.txt Edgar Link pending
0000950170-24-091193-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img260269913_0.jpg Edgar Link pending
md-20240630.htm Edgar Link pending
md-20240630.xsd Edgar Link pending
md-ex10_1.htm Edgar Link pending
md-ex31_1.htm Edgar Link pending
md-ex31_2.htm Edgar Link pending
md-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
md-20240630_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending